-
Mashup Score: 0
David S. Hong, MD, discusses updated findings from an analysis of 3 trials which ultimately led to the approval of larotrectinib for patients with solid tumors who harbor an NTRK fusion.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
A phase 1/2 trial investigating GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas will begin following the acceptance of an investigational new drug application for the agent.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0COVID-19 Vaccines Deemed Safe for Patients With Solid Tumors - 1 year(s) ago
Patients with solid tumors do not appear to have an increased risk of side effects from COVID-19 vaccination, according to a systematic review.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
A full approval has been granted to pembrolizumab by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
As of March 28, 2023, the partial clinical hold on the phase 1/2 VELA trial, which is evaluating the selective CDK2 inhibitor BLU-222 for patients with solid tumors, has been lifted. Blueprint Medicines has resumed the re-initiation of patient enrollment.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Expert Marks Anti-VISTA/Anti-PD-1 Therapies as a Potential New Strategy for Advanced Solid Tumors - 1 year(s) ago
Anti-VISTA therapy may be the therapy type to be used with PD-1/PD-L1 inhibitors to treat patients with advanced solid tumors, expert say. One agent, KVA12123, has just entered phase 1 clinical research.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
A new study offers a potential strategy to improve T-cell therapy in solid tumors through simultaneous knockout of two inflammatory regulators.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 1
The START-001 trial will administer STAR0602 to patients with PD-1 refractory advanced solid tumors in order to evaluate the safety, tolerability, and preliminary clinical activity of the agent as a monotherapy.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Teon Therapeutics and Merck Will Assess TT-816/Pembrolizumab in Advanced Solid Tumors - 1 year(s) ago
Teon Therapeutics has entered into a clinical trial collaboration with Merck to assess TT-816 and pembrolizumab in a phase 1/2 study.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors - npj Precision Oncology - 1 year(s) ago
We designed a liquid biopsy (LB) platform employing low-pass whole genome sequencing (LP-WGS) and targeted sequencing of cell-free (cf) DNA from plasma to detect genome-wide copy number alterations (CNAs) and gene fusions in pediatric solid tumors. A total of 143 plasma samples were analyzed from 19 controls and 73 patients, including 44 bone or soft-tissue sarcomas and 12 renal, 10 germ cell,…
Source: NatureCategories: General Medicine News, Latest HeadlinesTweet
David S. Hong, MD, discusses updated findings from an analysis of 3 trials which ultimately led to the approval of #larotrectinib for patients with #solidtumors who harbor an NTRK fusion. #lcsm | @MDAndersonNews https://t.co/ovURWh1gZK